TMS Therapy
Success Rate

The introduction of transcranial magnetic stimulation (TMS) for treating major depressive disorder (MDD) has been a gift for individuals who did not respond to traditional antidepressants. In fact, according to recent studies, only about 50% of the patients trying SSRIs, SRNIs, and tricyclic medications to alleviate depressive symptoms found the drugs to be effective. There were few alternative options until 2008, when the FDA approved the first TMS device for treating depression.

The U.S. government and research community gathered extensive evidence of the efficacy of TMS therapy for MDD, obsessive-compulsive disorder (OCD), tobacco use disorder, and anxiety, which made it accessible for people struggling with these conditions. Many clinical studies have demonstrated that this treatment is safe and effective. Individuals who joined the trials experienced high response and remission rates, significantly improving their symptoms and well-being. TMS clinics worldwide see firsthand the impressive changes this therapy brings.

TMS Therapy
Success Rate

table of contents

Table Of Contents

Studies Demonstrate
High Success Rates of TMS

Since the early 2000s, clinical trials of TMS have continued to show promising results for individuals struggling with various mental health disorders. Success rates are measured using standardized assessment instruments, such as the Hamilton Depression Rating Scale, the Beck Depression Inventory, the Hamilton Anxiety Rating Scale, the Clinical Global Impression, and other tools. Here is an overview of studies demonstrating the safety and efficacy of TMS therapy for treating severe depression, OCD, tobacco use disorder, and anxiety.

Success Rates for Major Depressive Disorder

One of the early meta-analyses, involving 1,092 patients in 24 studies, found that repetitive transcranial magnetic stimulation (rTMS) improved symptoms and produced a robust clinical response. The authors concluded that TMS provides significant benefits in short-term studies. Newer evidence confirms these findings and provides additional insights into the effectiveness of different types of TMS for treatment-resistant depression.

Here is an overview of recent research:

In their 2023 study, Roth et al. found that 80% of patients experienced improvements after accelerated dTMS, and their remission rates were 51%.

A 2021 study by Miron et al. revealed that the response rates for rTMS were 40-50%, while the remission rates were 25-30%.

Vida et al. (2023) conducted a meta-analysis that reached similar results for rTMS, with the average response and remission rates being 40% and 36%, respectively.

A 2020 article published by Harvard Medical School confirms the numbers of rTMS, showing response and remission rates of 50-60% and 33%.

Recent research provides promising evidence for using TMS in treating depression. Response rates, indicating significant symptom improvement, range from 40-60% across multiple studies. Remission rates, with minimal remaining symptoms, are typically reported between 30-50%. Deep transcranial magnetic stimulation demonstrates even better clinical outcomes in available research and our practice.

Overall, TMS treatment is an excellent option for patients with MDD, providing much-needed relief when other therapies have not been successful. Equipment and protocols continuously improve, allowing practitioners to achieve better results every year. Current evidence supports TMS as a viable path forward for patients who want their major depressive disorder treated with maximum safety and effectiveness.

Success Rates for OCD

OCD is a chronic mental health condition marked by intrusive, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) that can severely impair a person’s ability to function. Traditionally, this disorder has been treated with cognitive-behavioral therapy (CBT), talk therapy, and medications like SSRIs. However, many patients do not respond to these treatments and need alternative options, such as TMS.

Since receiving FDA clearance for OCD in 2018, dTMS has shown promising results, offering a new avenue of hope for those who struggle with this condition. Studies suggest that deep TMS treatment can significantly reduce both the severity and frequency of OCD symptoms, especially when combined with other therapeutic approaches.

Research on TMS for OCD

Numerous studies have demonstrated that deep TMS is an effective treatment for OCD when applied to the prefrontal cortex and anterior cingulate cortex (areas linked to dysfunctional behaviors). Many patients experience a notable decrease in obsessions and compulsions after a course of TMS sessions.

Here are the success rates of TMS therapy for OCD:

Roth et al. (2021) studied 22 clinical sites where 219 individuals received dTMS. The researchers found that 57.8% of participants achieved at least a 30% reduction in OCD symptoms.

A 2022 study by Gersner et al. reported that approximately 58% of patients treated with dTMS experienced significant improvements, while about 32% had complete remission.

Recent research by Fitzsimmons et al. (2024) showed that rTMS can also be an effective treatment for patients with OCD. The authors tested three rTMS protocols, which led to an average response rate of 57.4%. None of the patients reported serious adverse events.

Real-World Outcomes

Beyond clinical trials, real-world data from TMS clinics supports these findings. Practitioners report that a substantial percentage of OCD patients experience marked improvements in their quality of life, with many achieving symptom relief that allows them to regain control over daily activities, relationships, and overall well-being.

We have observed high success rates, with people reporting reduced intrusive thoughts, decreased compulsive behaviors, and a return to a more balanced, fulfilling life. Many treatment-resistant patients notice improvements after just a few weeks of acute treatment, and this progress continues throughout the therapy.

Success Rates for Smoking Cessation

Smoking cessation is one of the most challenging health goals for many individuals, especially for those who have struggled with nicotine addiction for years. Traditional methods, such as nicotine replacement therapy, counseling, and prescription medications, can be helpful. However, success rates remain relatively low, with long-term abstinence challenging to achieve. This is where TMS has emerged as a promising alternative for smoking cessation.

TMS therapy targets brain regions associated with addiction, particularly the prefrontal cortex and insula, which are involved in cravings and impulse control. By modulating the neural activity in these areas, TMS has been shown to reduce withdrawal symptoms, helping individuals avoid smoking.

Research on TMS for Smoking Cessation

While TMS was initially developed for major depression, its success has led to exploration in other areas, including nicotine addiction. Many studies have demonstrated that this therapy can be an effective tool for helping people quit smoking:

Multicenter research by Zangen et al. (2021) revealed that 28% of participants stopped consuming nicotine for at least 4 weeks after undergoing bilateral dTMS.

In a study by Li et al. (2020), 23.8% of patients quit smoking by the target date. The researchers used an rTMS protocol, which confirmed earlier findings by other scholars.

A recent study published in Brain Stimulation demonstrated that the abstinence rates reached 82.4% among individuals who had undergone dTMS treatment.

Real-World Outcomes

TMS in real-world clinical settings has shown comparable results to those seen in trials, with many patients reporting reduced cravings after just a few weeks of therapy. The success rates are higher among patients who combine TMS with behavioral counseling and nicotine replacement therapy. The non-invasive nature of TMS, along with its ability to address both the psychological and physiological aspects of nicotine addiction, makes it a valuable addition to smoking cessation programs.

Research on TMS for Anxiety

The number of studies on the use of TMS to treat anxiety disorders is growing every year. New protocols are being proposed that increase the effectiveness of this treatment and help patients relieve symptoms.

Here is an overview of recent evidence:

A randomized controlled trial by Dilkov et al. (2017) tested TMS for individuals with GAD. It concluded that those receiving this therapy showed a clinically significant decrease in anxiety symptoms versus the sham group.

Deifenbach et al.’s (2019) study of GAD patients demonstrated higher response and remission rates among individuals who underwent rTMS treatment.

Research conducted by Clarke et al. (2019) showed that rTMS treatment led to a 23.3% remission rate among patients with comorbid depression and anxiety.

In clinical practice, TMS therapy for anxiety disorders has been growing in popularity. Many TMS clinics report that patients experience reduced anxiety, improved emotional regulation, and a decrease in physical symptoms, such as tension and panic attacks. This treatment can be highly beneficial for many individuals who struggle with traditional treatments for anxiety disorders.

Real-World Outcomes

TMS trials continue to be conducted globally to assess the value of this therapy in treating mental health conditions. As new potential applications are considered in medicine and psychiatry, clinical studies of TMS will continue to broaden. Our comprehensive database allows patients to find the most reputable clinics in their areas to receive evidence-based care from licensed providers.

TMS Therapy Success Rate

Studies DemonstrateHigh Success Rates of TMS

Success Rates for Major Depressive Disorder

Success Rates for OCD

Research on TMS for OCD

Real-World Outcomes

Success Rates for Smoking Cessation

Research on TMS for Smoking Cessation

Real-World Outcomes

Research on TMS for Anxiety

Real-World Outcomes

TMS Therapy
Success Rate

Studies Demonstrate
High Success Rates of TMS